News | February 24, 2012

CardioInsight Completes First Commercial Product Installation of its ECVUE Cardiac Mapping System

The ECVUE System provides detailed images of the heart

February 24, 2012 — CardioInsight Technologies Inc. announced that it has successfully completed the European commercial introduction of its ECVUE system to aid in the diagnosis of cardiac arrhythmias. St. Mary's Hospital in London became the company's first commercial customer.  Doctors Prapa Kanagaratnam, Wyn Davies, Nick Peters, David Lefroy, Boon Lim and Shahnaz Jamil-Copley demonstrated the system's effectiveness in a day-to-day clinical setting, completing five clinical cases during its first week of clinical use.

"We are excited to be CardioInsight's first commercial partner and I was very impressed with the ECVUE system's unique ability to display global cardiac activation without the need for an invasive study," said Dr. Prapa Kanagaratnam, the clinical lead for cardiac electrophysiology at St. Mary's Hospital, Imperial College Healthcare. "I think there is a real potential that this could be a disruptive technology that produces a paradigm shift in our approach to managing patients with cardiac arrhythmias."

St. Mary's Hospital has long been recognized as a leading institution in the study of cardiac electrophysiology, dating back to the first systematic clinical use of electrical recordings of the heart's activity in the early 1900's.  Dr. Davies and his team later became a pioneering center for catheter-based 3D mapping.

"We are proud to have the opportunity to work with the world-class team from St. Mary's Hospital as we look to demonstrate the clinical impact of the ECVUE system," said Steve Arless, CEO of CardioInsight.  "I believe their commitment to help pioneer our non-invasive mapping system is a testament to the ECVUE system's clinical potential, and we look forward to further demonstrating this potential under their guidance."

The commercial installation at St. Mary's Hospital is the first of a focused commercial introduction of the ECVUE system in Europe to demonstrate the unique ability to simplify cardiac mapping procedures, reduce procedure time, and expand the use of mapping to new applications.

For more information:

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init